MedTrace Logo

AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)

NCT01215279 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2014-10-23

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to investigate the tolerability and safety of AZD2423 in Patients with chronic obstructive pulmonary disease.

Conditions

Interventions

DRUG

AZD2423

100 mg oral treatment once daily for 28 days

DRUG

Placebo to AZD2423

Oral treatment once daily for 28 days

Sponsors & Collaborators

Principal Investigators

  • Joanna Marks-Konczalik, MD, PhD · AstraZeneca R&D

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Bulgaria
  • Slovakia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01215279 on ClinicalTrials.gov